Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flualamide SCHEMBL29804765 | 1.00 | MCHR1 (0.58) | MCHR1NPC1RAB9ASLC22A2SLC22A1 | |
| Alloclamide SCHEMBL872157 | 0.84 | MCHR1 (0.53) | MCHR1RAB9ASLC22A1ALDH1A1LMNA | |
| Alloclamide SCHEMBL29730070 | 0.84 | MCHR1 (0.53) | MCHR1RAB9ASLC22A1ALDH1A1LMNA | |
| Alloclamide SCHEMBL209095 | 0.83 | MCHR1 (0.52) | MCHR1RAB9ASLC22A1ALDH1A1LMNA | |
| Alloclamide SCHEMBL27527103 | 0.82 | MCHR1 (0.51) | MCHR1RAB9ASLC22A1ALDH1A1LMNA | |
| SCHEMBL6365174 | 0.81 | LIG1 (0.60) | MCHR1SLC22A2SLC22A1ALDH1A1LMNA | |
| SCHEMBL20471847 | 0.77 | CFTR (0.55) | NPC1RAB9AALDH1A1LMNATSHR | |
| SCHEMBL11787896 | 0.77 | RAB9A (0.59) | MCHR1RAB9AALDH1A1MAPK1 | |
| SCHEMBL15126164 | 0.76 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL20471972 | 0.75 | GAA (0.45) | RAB9AALDH1A1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116622050-B | Low-density wear-resistant anti-skid polyurethane sole resin and preparation method and application thereof | 山东一诺威聚氨酯股份有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-116622050-A | Low-density wear-resistant anti-skid polyurethane sole resin and preparation method and application thereof | 山东一诺威聚氨酯股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| CN-117500800-A | (thio) oxazoline insecticide | 礼蓝动物保健有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117430782-A | Resin for high-brightness pore-free polyurethane sole, and preparation method and application thereof | 山东一诺威聚氨酯股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-116622050-B | Low-density wear-resistant anti-skid polyurethane sole resin and preparation method and application thereof | 山东一诺威聚氨酯股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-116622050-A | Low-density wear-resistant anti-skid polyurethane sole resin and preparation method and application thereof | 山东一诺威聚氨酯股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115477737-B | Hydrolysis-resistant and flex-resistant polyurethane sole resin composition and preparation and application thereof | 山东一诺威聚氨酯股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115477737-A | Hydrolysis-resistant and flex-resistant polyurethane sole resin composition and preparation and application thereof | 山东一诺威聚氨酯股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | MCHR1 2689/4885NPC1 787/4885RAB9A 1754/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | MCHR1 2626/4885NPC1 1049/4885RAB9A 2303/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | MCHR1 2423/4885NPC1 533/4885RAB9A 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.